Top 5 Stocks Under $5 That Could Triple

2. AtaiBeckley Inc. (NASDAQ:ATAI)

AtaiBeckley Inc. (NASDAQ:ATAI) earns a place on our list of the top 10 stocks under $5 that could triple.

Analysts are strongly supportive of AtaiBeckley Inc. (NASDAQ:ATAI) amid recent clinical updates.

H.C. Wainwright reaffirmed its “Buy” rating and $25.00 price target on March 17, 2026, indicating significant upside from the current $3.65 level.

The recent Phase 2a data for BPL-003 bolstered confidence in AtaiBeckley Inc. (NASDAQ:ATAI)’s pipeline. The findings reinforced the company’s position in the 5-MeO-DMT class by demonstrating that a single dose produces a therapeutic effect that intensifies over time and lasts for at least 12 weeks.

The data, which highlights rising confidence in AtaiBeckley Inc. (NASDAQ:ATAI)’s clinical differentiation of the asset, was cited by the firm as a strong signal that continues to set the benchmark for the class.

AtaiBeckley Inc. (NASDAQ:ATAI), following an end-of-Phase 2 meeting, reached an agreement with the FDA on the dual-trial design for its planned Phase 3 program. This milestone supports the overall momentum and keeps the program on schedule for launch in Q2 2026. Prior to this, BPL-003 was designated as a Breakthrough Therapy in October 2025.

Srinivas Rao, Co-Founder and CEO, stated,

“BPL-003 has demonstrated rapid, durable antidepressant effects, and the FDA’s supportive End-of-Phase 2 feedback enables us to advance into two parallel Phase 3 trials beginning in Q2 2026. With Breakthrough Therapy Designation and a robust pivotal design, we believe BPL‑003 has the potential to meaningfully reshape the treatment landscape for TRD.”

AtaiBeckley Inc. (NASDAQ:ATAI), a clinical-stage biopharmaceutical company, focuses on developing effective, rapid-acting, and convenient mental health treatments.